8-K ·Filed Jul 28, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001437749-26-024560
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a routine governance filing with no trading implications. Monitor next quarterly report for pipeline updates and cash runway, which are the primary value drivers for VXRT.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
VXRT ▲ +4.17% at T+20d
NEUTRAL call ✓ call won +4.17% · α vs SPY +0.79% · entry $0.4800 → $0.5000
Next anchor: T+60d in 19d
Latest observation: T+45 +22.77% FF3 residual α
Entry anchored
Jul 28, 2026
via day open
T+1d
0.00%
call 0.00% · α +1.54%
$0.4800
settled 2mo ago
T+5d
+25.00%
call +25.00% · α +20.89%
$0.6000
settled 8w ago
T+20d
+4.17%
call +4.17% · α +0.79%
$0.5000
settled 5w ago
T+60d
—
call — · α —
—
in 19d

Price Chart

Loading chart...

Executive Summary

Vaxart filed an 8-K reporting a routine reorganization of its Board committees, appointing Kevin P. Finney as chair of the Nominating and Governance Committee and James B. Breitmeyer as chair of the Compensation Committee, effective August 1, 2026. This is an administrative governance change with no financial or operational impact on the company's business, pipeline, or financial position. The filing contains no financial data, guidance, or material events.

Key Facts

  • Board reorganized Nominating and Governance Committee and Compensation Committee on July 27, 2026.
  • Kevin P. Finney appointed chair of Nominating and Governance Committee.
  • James B. Breitmeyer, M.D., Ph.D. appointed chair of Compensation Committee.
  • Changes effective August 1, 2026.
  • No financial data, guidance, or material business events disclosed.

Financial Impact

None — no financial impact disclosed.

Risk Factors

  • No material risks disclosed in this filing.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-024560
Document: 0001437749-26-024560-index-headers.html0001437749-26-024560
Document: 0001437749-26-024560-index.html0001437749-26-024560
Document: 0001437749-26-024560.txt0001437749-26-024560
21 reports for VXRT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +37.66%May 1, 2026
Filters
Rows
Reports for VXRT — sortable, filterable
TypeNow
Jul 28, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$0.4800 $0.5000▲ +4.17%▲ +0.79%$0.4400 (−8.33%)
Jul 7, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$0.5500 $0.6000▲ +9.09%▲ +5.93%$0.4400 (−20.00%)
Jul 6, 2026
12w ago
DEFA14A
NEUTRAL ★ 5/10
$0.6200 $0.5900▼ −4.84%▼ −5.69%$0.4400 (−29.03%)
Jul 2, 2026
13w ago
DEFA14A
BULLISH ★ 5/10
$0.6400 $0.5490▼ −14.22%▼ −14.52%$0.4400 (−31.25%)
Jul 2, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$0.6400 $0.5200▼ −18.75%▼ −18.34%$0.4400 (−31.25%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
8-K
MIXED ★ 5/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 16, 2026
15w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5600 $0.5300▼ −5.36%▼ −6.21%$0.4400 (−21.43%)
Jun 8, 2026
16w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5800 $0.5502▼ −5.14%▼ −6.53%$0.4400 (−24.14%)
Showing 10 of 21

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access